公司概述
AbbVie Inc. operates as a research-based biopharmaceutical entity dedicated to the global research, development, manufacturing, and commercialization of therapeutic medicines. The company functions within the healthcare sector, specifically categorized under the industry of drug manufacturers, which implies a focus on innovation and regulatory compliance to bring life-saving treatments to market. AbbVie Inc. currently maintains a substantial market capitalization of $375.69 billion, reflecting its status as a major player in the pharmaceutical landscape, while generating annual revenue of $61.16 billion and employing a workforce of 57,000 individuals. These financial figures and operational scale indicate that AbbVie possesses significant resources to sustain extensive R&D pipelines and maintain a dominant position in the commercialization of key therapies such as Skyrizi, Rinvoq, and Imbruvica.
财务健康
The company reported a trailing twelve-month revenue of $61.16 billion and net income of $4.19 billion, supported by an EBITDA of $29.25 billion, which highlights a distinct gap between top-line revenue and bottom-line profit that reveals a substantial cost structure involving operating expenses, taxes, and interest. AbbVie generated free cash flow of $18.34 billion, a metric that underscores the company's robust financial flexibility to fund future research initiatives, manage large debt obligations, and return capital to shareholders. The company's profitability efficiency is detailed by three key margins: a gross margin of 71.6%, which indicates high pricing power and efficient production costs; an operating margin of 34.1%, demonstrating effective management of overhead and operational expenses; and a profit margin of 6.9%, which reflects the final earnings available after all costs. On the balance sheet, the company holds $5.26 billion in cash against $68.40 billion in debt, while the debt-to-equity ratio is listed as N/A, suggesting a capital structure heavily reliant on equity financing or specific accounting treatments rather than traditional leverage metrics. Liquidity is assessed via a current ratio of 0.67, which indicates that short-term assets are insufficient to cover short-term liabilities without the need for refinancing or asset liquidation, pointing to potential liquidity pressure. Return metrics show a return on equity of 6225.0% and a return on assets of 9.8%, where the exceptionally high ROE suggests significant leverage or accounting adjustments in equity, while the ROA indicates moderate efficiency in generating profits from the total asset base.
估值评估
Valuation metrics for AbbVie Inc. include a trailing twelve-month P/E ratio of 89.24 and a forward P/E of 13.21, a stark divergence that implies the market expects a dramatic normalization of earnings or a significant change in accounting treatment that will drastically lower future earnings per share compared to current historical levels. The price-to-book ratio stands at -114.81, a negative figure that indicates the market is pricing the company based on intangible assets and future earnings potential rather than tangible book value, effectively removing traditional book value comparisons from relevance. Alternative valuation measures such as a price-to-sales ratio of 6.14 and an EV/EBITDA of 15.00 suggest the market is willing to pay a premium for revenue and cash generation despite the high trailing multiple. The stock has traded between a 52-week low of $164.39 and a 52-week high of $244.81, meaning the current price sits at a level that requires precise calculation relative to this range to determine if it is near historical extremes. The beta of 0.36 indicates that the stock exhibits significantly lower volatility relative to the broader market, behaving more like a defensive asset than a typical growth biotech stock.
Growth & Income
Revenue growth for the trailing twelve months is recorded at 10.0%, while earnings growth is listed as N/A, preventing a direct comparison of earnings velocity against revenue expansion but suggesting that profitability dynamics may be stabilizing or undergoing structural changes. As a dividend payer, AbbVie offers a dividend yield of 3.3% with a payout ratio of 276.8%, which presents a sustainability challenge as the ratio exceeds 100%, indicating that dividends are currently being funded from cash reserves or debt rather than current net income. Since the earnings growth rate is unavailable, it is not possible to confirm if earnings are growing faster or slower than revenue, but the high payout ratio necessitates reliance on free cash flow of $18.34 billion to maintain the current income stream. The overall profile combines a high-yield dividend with moderate revenue expansion and a low-beta volatility, positioning the asset as an income-focused holding with specific financial constraints regarding its capital structure.